Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$10.96+0.8%$9.52$6.32▼$20.56$192.79M2.68311,560 shs240,983 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%+10.02%+10.47%+38.83%+76.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$10.96+0.8%$9.52$6.32▼$20.56$192.79M2.68311,560 shs240,983 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%+10.02%+10.47%+38.83%+76.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 2.82Moderate Buy$43.88300.32% UpsideCurrent Analyst Ratings BreakdownLatest CRBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/20/2026CRBPCorbus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/10/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $57.002/18/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$78.54M-$5.98N/AN/AN/AN/A-65.76%-57.88%5/12/2026 (Estimated)Latest CRBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26N/AN/AN/AN/AN/A3/9/2026Q4 2025CRBPCorbus Pharmaceuticals-$1.78-$1.25+$0.53-$1.25$1.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A8.078.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4017.74 million17.12 millionOptionableCRBP HeadlinesRecent News About These CompaniesCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026May 5, 2026 | globenewswire.comCorbus Pharmaceuticals (CRBP) Expected to Announce Quarterly Earnings on TuesdayMay 3, 2026 | americanbankingnews.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by BrokeragesMay 3, 2026 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Earns Buy Rating from Analysts at GuggenheimMay 2, 2026 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by GuggenheimMay 1, 2026 | marketbeat.comGuggenheim initiates coverage of Corbus Pharmaceuticals Holdings (CRBP) with buy recommendationApril 30, 2026 | msn.comCorbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?April 25, 2026 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" RatingApril 25, 2026 | marketbeat.comCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701April 24, 2026 | finance.yahoo.comCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701April 22, 2026 | markets.businessinsider.comCorbus Pharmaceuticals Updates Executive Employment Agreements and ProtectionsApril 19, 2026 | theglobeandmail.comMizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash ValueApril 17, 2026 | finance.yahoo.comMizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash ValueApril 17, 2026 | insidermonkey.com5 Best Biotech Stocks Under $10 to BuyApril 15, 2026 | insidermonkey.comCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for ObesityApril 14, 2026 | finance.yahoo.comCorbus Pharmaceuticals (CRBP) Gets a Buy from WedbushApril 10, 2026 | theglobeandmail.comCorbus reaches FDA agreement on development path for cancer drug CRB-701April 7, 2026 | msn.comCorbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical CancerApril 7, 2026 | finance.yahoo.comAssenagon Asset Management S.A. Has $1.53 Million Holdings in Corbus Pharmaceuticals Holdings, Inc. $CRBPMarch 31, 2026 | defenseworld.netDCorbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health SummitMarch 18, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$10.96 +0.09 (+0.83%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$11.07 +0.11 (+1.04%) As of 05/8/2026 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
